Cargando…

Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration

AIMS: To test the hypothesis that patients treated for neovascular age related macular degeneration (nAMD) with longer treatment intervals are more likely to persist with treatment. METHODS: Data were obtained from the prospectively-defined Fight Retinal Blindness! registry. Treatment interval at 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teo, Kelvin Y. C., Nguyen, Vuong, O’Toole, Louise, Daien, Vincent, Sanchez-Monroy, Jorge, Ricci, Federico, Ponsioen, Theodorus Leonardus, Morros, Helena Brosa, Cheung, Chui Ming Gemmy, Arnold, Jennifer J., Barthelmes, Daniel, Gillies, Mark C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905488/ https://www.ncbi.nlm.nih.gov/pubmed/35140329 http://dx.doi.org/10.1038/s41433-022-01957-z

Ejemplares similares

Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence
por: Teo, Kelvin Yi Chong, et al.
Publicado: (2020)

Real‐world treatment outcomes of neovascular Age‐related Macular Degeneration in the Netherlands
por: Verbraak, Frank D., et al.
Publicado: (2020)

Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis
por: Gabrielle, Pierre-Henry, et al.
Publicado: (2021)

ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR
por: Nguyen, Vuong, et al.
Publicado: (2021)

Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age‐related macular degeneration in daily clinical practice: data from the FRB! registry
por: Gabrielle, Pierre‐Henry, et al.
Publicado: (2022)

Neovascular age‐related macular degeneration: A review of findings from the real‐world Fight Retinal Blindness! registry
por: Nguyen, Vuong, et al.
Publicado: (2021)

Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
por: Hunt, Adrian Robert, et al.
Publicado: (2023)

Macular neovascularization in eyes with pachydrusen
por: Teo, Kelvin Yi Chong, et al.
Publicado: (2021)

The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration
por: Teo, Kelvin Yi Chong, et al.
Publicado: (2018)

Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2‐year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry
por: Gabrielle, Pierre‐Henry, et al.
Publicado: (2021)

COVID-19-Related Retinal Micro-vasculopathy – A Review of Current Evidence
por: Teo, Kelvin YC, et al.
Publicado: (2022)

Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience
por: Debourdeau, Eloi, et al.
Publicado: (2023)

Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
por: Bhandari, Sanjeeb, et al.
Publicado: (2022)

Keeping our eyecare providers and patients safe during the COVID-19 pandemic
por: Teo, Kelvin Yi Chong, et al.
Publicado: (2020)

Quality of life impact of eye diseases: a Save Sight Registries study
por: Kandel, Himal, et al.
Publicado: (2022)

Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study
por: Hamilton, Robin D., et al.
Publicado: (2020)

Evolving treatment paradigms for PCV
por: Fenner, Beau J., et al.
Publicado: (2021)

CORRELATION BETWEEN ATROPHY-TRACTION-NEOVASCULARIZATION GRADE FOR MYOPIC MACULOPATHY AND CLINICAL SEVERITY
por: Ruiz-Medrano, Jorge, et al.
Publicado: (2021)

Beat cues facilitate time estimation at longer intervals
por: Torres, Nathércia L., et al.
Publicado: (2023)

Contribution of common and rare variants to Asian neovascular age-related macular degeneration subtypes
por: Fan, Qiao, et al.
Publicado: (2023)

Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration
por: Ozdemir, Semra, et al.
Publicado: (2022)

Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence
por: Daien, Vincent, et al.
Publicado: (2021)

Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER
por: Tadayoni, Ramin, et al.
Publicado: (2023)

A serum metabolomics study of patients with nAMD in response to anti-VEGF therapy
por: Gao, Yan, et al.
Publicado: (2020)

Impact of Loading Phase, Initial Response and CFH Genotype on the Long-Term Outcome of Treatment for Neovascular Age-Related Macular Degeneration
por: Menghini, Moreno, et al.
Publicado: (2012)

Intravitreal Aflibercept Versus Photodynamic Therapy in Chinese Patients with Neovascular Age-Related Macular Degeneration: Outcomes of the SIGHT Study
por: Li, Xiaoxin, et al.
Publicado: (2017)

A Longer Interstimulus Interval Yields Better Learning in Adults and Young Adolescents
por: Kjell, Katarina, et al.
Publicado: (2018)

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
por: Milz, Ruth, et al.
Publicado: (2023)

Initial observation or treatment for diabetic macular oedema with good visual acuity: two‐year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry
por: Gabrielle, Pierre‐Henry, et al.
Publicado: (2020)

Outcomes of Over 40,000 Eyes Treated for Diabetic Macula Edema in Routine Clinical Practice: A Systematic Review and Meta-analysis
por: Mehta, Hemal, et al.
Publicado: (2022)

Weight gain during acute treatment of an initial pulmonary exacerbation is associated with a longer interval to the next exacerbation in adults with cystic fibrosis
por: Barr, Helen L., et al.
Publicado: (2017)

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA
por: Ferreira, Alberto, et al.
Publicado: (2015)

Differential reperfusion patterns in retinal vascular plexuses following increase in intraocular pressure an OCT angiography study
por: Cheung, Chui Ming Gemmy, et al.
Publicado: (2020)

Correlation of choriocapillaris hemodynamic data from dynamic indocyanine green and optical coherence tomography angiography
por: Cheung, Chui Ming Gemmy, et al.
Publicado: (2021)

Chronic Manganese Administration with Longer Intervals Between Injections Produced Neurotoxicity and Hepatotoxicity in Rats
por: Fan, Xi-Min, et al.
Publicado: (2020)

Neovascular glaucoma: prevention and treatment
por: Mohamed-Noriega, Jibran, et al.
Publicado: (2021)

Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy
por: Vyas, Chinmayi Himanshuroy, et al.
Publicado: (2021)

THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry
por: Gabrielle, Pierre-Henry, et al.
Publicado: (2022)

Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA
Publicado: (2015)

Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration
por: Khachigian, Levon M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p1rk9tdmliii8apsrc1b4feeam